Pharmaceuticals News and Research

RSS

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Valeant Pharmaceuticals International today announced first quarter financial results for 2010.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

Investment report on Spectrum Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Spectrum Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

UBC announces acquisition of ABS

United BioSource Corporation today announced the acquisition of Abt Bio-Pharma Solutions, Inc., a Boston, Massachusetts-based provider of health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries.

3 May 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2010, reporting a net loss of $14.8 million or ($0.18) per share.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

3 May 2010

Sistemic announces availability new SistemRNA Technology

Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.

3 May 2010

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid.

3 May 2010

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.

3 May 2010

BSGI improves breast cancer detection

A new study, presented at the American Society of Breast Surgeons Annual Meeting in Las Vegas, found that Breast-Specific Gamma Imaging (BSGI) is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy.

3 May 2010

Watson Pharmaceuticals sued in connection with filing ANDA for generic equivalent of Trilipix

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with the filing of Watson's Abbreviated New Drug Application for choline fenofibrate delayed-release capsules in the 45 mg and 135 mg strengths.

3 May 2010

Research roundup: Managing nursing home patients, streamlining medical billing, financial disclosures

Saving Billions Of Dollars--And Physicians' Time--By Streamlining Billing Practices - "The U.S. system of billing third parties for health care services is complex, expensive, and inefficient," write the authors, who analyzed Massachusetts General Physicians Organization staffing and cost data in fiscal year 2006.

3 May 2010

Patients, research participants favor disclosure of financial relationships between medicine and industry

A review and analysis of previously published studies finds that patients, research participants and journal readers believe financial relationships between medicine and industry should be disclosed, in part because those financial ties may influence research and clinical care, according to a report in the April 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

3 May 2010

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Natural S-equol, a novel soy germ-based compound, is very likely the primary ingredient for reducing hot flushes in the dietary supplement SE5-OH, which is under development for reduction of menopause symptoms, according to pre-clinical efficacy data from studies using an animal model presented at the Experimental Biology 2010 annual meeting.

3 May 2010

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.

3 May 2010

Vitamin E effective in treating NASH: Study

Vitamin E has been shown effective in treating nonalcoholic steatohepatitis, an obesity-associated chronic liver disease that can lead to cirrhosis, liver cancer, and death. NASH also is related to or a part of type 2 diabetes, lipid disorders and cardiovascular disease.

3 May 2010

Codeine containing preparations lose their OTC status

It will get more difficult to procure Codeine based pain killers, cough syrups etc. from the local pharmacists from now on. There have been new restrictions over codeine based drugs like Nurofen Plus, Panadeine and Mersyndol which were initially sold over the counter but lost this OTC status with effect from May 1st 2010. The National Drugs and Poisons Schedule Committee formulated the changes during meetings in June and October last year.

2 May 2010

Seasonal flu vaccine ups the risk of getting H1N1 flu

Initial reports linking seasonal flu vaccine and getting swine flu or H1N1 flu emerged September 2009 in Canada. In spring 2009 many people who acquired pandemic H1N1 flu had been initially vaccinated with seasonal flu vaccine. This triggered four additional studies in Canada to explore the link further. The studies included 2,700 patients with or without H1N1. The first of the studies showed a surprising 68 percent rise of risk of development of H1N1 flu in those vaccinated with seasonal flu shot. The other 3 studies showed increase of risk of H1N1 flu by 1.4 to 1.5 times with the original flu shot.

2 May 2010

Pharmaceuticals News and Research

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Investment report on Spectrum Pharmaceuticals

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

UBC announces acquisition of ABS

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

Sistemic announces availability new SistemRNA Technology

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

BSGI improves breast cancer detection

Watson Pharmaceuticals sued in connection with filing ANDA for generic equivalent of Trilipix

Research roundup: Managing nursing home patients, streamlining medical billing, financial disclosures

Patients, research participants favor disclosure of financial relationships between medicine and industry

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

Vitamin E effective in treating NASH: Study

Codeine containing preparations lose their OTC status

Seasonal flu vaccine ups the risk of getting H1N1 flu

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News